241 related articles for article (PubMed ID: 8142362)
1. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.
Lawrence DA; Olson ST; Palaniappan S; Ginsburg D
Biochemistry; 1994 Mar; 33(12):3643-8. PubMed ID: 8142362
[TBL] [Abstract][Full Text] [Related]
2. Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1.
Gils A; Lu J; Aertgeerts K; Knockaert I; Declerck PJ
FEBS Lett; 1997 Sep; 415(2):192-5. PubMed ID: 9350994
[TBL] [Abstract][Full Text] [Related]
3. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Wojtowicz A; Selman SH; Jankun J
Mol Cancer Ther; 2003 Jan; 2(1):19-28. PubMed ID: 12533669
[TBL] [Abstract][Full Text] [Related]
4. The role of His(143) for the pH-dependent stability of plasminogen activator inhibitor-1.
Sui GC; Mångs H; Wiman B
Biochim Biophys Acta; 1999 Sep; 1434(1):58-63. PubMed ID: 10556559
[TBL] [Abstract][Full Text] [Related]
5. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.
Audenaert AM; Knockaert I; Collen D; Declerck PJ
J Biol Chem; 1994 Jul; 269(30):19559-64. PubMed ID: 8034724
[TBL] [Abstract][Full Text] [Related]
6. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.
Gils A; Knockaert I; Declerck PJ
Biochemistry; 1996 Jun; 35(23):7474-81. PubMed ID: 8652525
[TBL] [Abstract][Full Text] [Related]
7. Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule.
Sui GC; Wiman B
Biochem J; 1998 Apr; 331 ( Pt 2)(Pt 2):409-15. PubMed ID: 9531478
[TBL] [Abstract][Full Text] [Related]
8. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Wang Q; Shaltiel S
BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
[TBL] [Abstract][Full Text] [Related]
9. The Bbeta-sheet in the PAI-1 molecule plays an important role for its stability.
Sui GC; Wiman B
Thromb Haemost; 2000 Jun; 83(6):896-901. PubMed ID: 10896245
[TBL] [Abstract][Full Text] [Related]
10. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
[TBL] [Abstract][Full Text] [Related]
11. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition.
Lawrence DA; Olson ST; Palaniappan S; Ginsburg D
J Biol Chem; 1994 Nov; 269(44):27657-62. PubMed ID: 7961684
[TBL] [Abstract][Full Text] [Related]
12. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
[TBL] [Abstract][Full Text] [Related]
13. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1.
Gils A; Declerck PJ
J Biol Chem; 1997 May; 272(19):12662-6. PubMed ID: 9139722
[TBL] [Abstract][Full Text] [Related]
14. Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants.
Lawrence DA; Strandberg L; Ericson J; Ny T
J Biol Chem; 1990 Nov; 265(33):20293-301. PubMed ID: 1700786
[TBL] [Abstract][Full Text] [Related]
15. 19F NMR studies of plasminogen activator inhibitor-1.
Abbott GL; Blouse GE; Perron MJ; Shore JD; Luck LA; Szabo AG
Biochemistry; 2004 Feb; 43(6):1507-19. PubMed ID: 14769027
[TBL] [Abstract][Full Text] [Related]
16. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms.
Sancho E; Declerck PJ; Price NC; Kelly SM; Booth NA
Biochemistry; 1995 Jan; 34(3):1064-9. PubMed ID: 7827021
[TBL] [Abstract][Full Text] [Related]
17. Characterization of plasminogen activator inhibitor 1 mutants containing the P13 to P10 region of ovalbumin or antithrombin III: evidence that the P13 residue contributes significantly to the active to substrate transition.
Gils A; Vleugels N; Tobback K; Knockaert I; Declerck PJ
Biochim Biophys Acta; 1998 Sep; 1387(1-2):291-7. PubMed ID: 9748634
[TBL] [Abstract][Full Text] [Related]
18. Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity.
Sherman PM; Lawrence DA; Verhamme IM; Paielli D; Shore JD; Ginsburg D
J Biol Chem; 1995 Apr; 270(16):9301-6. PubMed ID: 7721851
[TBL] [Abstract][Full Text] [Related]
19. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
Jankun J; Aleem AM; Selman SH; Basrur V; Skrzypczak-Jankun E
Int J Mol Med; 2009 Jan; 23(1):57-63. PubMed ID: 19082507
[TBL] [Abstract][Full Text] [Related]
20. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism.
Shore JD; Day DE; Francis-Chmura AM; Verhamme I; Kvassman J; Lawrence DA; Ginsburg D
J Biol Chem; 1995 Mar; 270(10):5395-8. PubMed ID: 7890653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
